Observational studyJournal of translational medicine2026

Baseline PD-L1 expression on circulating immune cells as a predictor of survival and immune-related adverse events in extensive-stage small-cell lung cancer patients treated with durvalumab and carboplatin-etoposide (NCT04712903 Trial).

Aida Piedra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.